Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $110.00. The company’s shares closed yesterday at $96.14.

Her work has previously appeared in Billboard and Reader's Digest. Jamie McCarthy/WireImage Josh Gad shared that he’s taking a GLP-1 medication for weight loss, praising it as a “miracle drug ...

Renowned investigative journalist Manasseh Awuni Azure has accused President Mahama of shielding former government officials accused of corruption. According to him, Mahama’s mass ...

In his investigation into the report of the Operation Recover All Loot (ORAL) team, investigative journalist Manasseh Awuni Azure has recommended the Mahama-led administration to avoid focusing on ...

Apple and Intel also managed modest gains, helping limit losses in the Nasdaq Composite. Daily Gilead Sciences, Inc CVS Health surged 13.6% after posting stronger-than-expected Q4 earnings ...